hiv drugs market to reach $15.5 billion by2014

Currently Approved Drugs for HIV: A Comparative Chart

twice a day is no more a problem.

http://www.aidsmeds.com/articles/DrugChart_10632.shtml


esearch and Markets: Global HIV Drugs Market 2010-2014 Report - The Global HIV Drugs Market to Reach US$15.5 Billion By 2014

Tue Feb 14, 2012 11:00am EST

http://www.reuters.com/article/2012/02/14/idUS178919+14-Feb-2012+BW20120214

Research and Markets: Global HIV Drugs Market 2010-2014 Report - The Global HIV Drugs Market to Reach US$15.5 Billion By 2014

Research and Markets (http://www.researchandmarkets.com/research/1f6344/global_hiv_drugs_m) has announced the addition of the "Global HIV Drugs Market 2010-2014" report to their offering.

One of the key factors contributing to this market growth is the increase in the use of highly active antiretroviral therapy. The Global HIV Drugs market has also been witnessing the need for novel HIV drugs. However, the expiration of patents of key drugs in 2010 could be a challenge to the growth of this market.

The report covers the segments such as Hospitals, Patient Diagnostic Centers, and Point-of-Care Centers. The report also analyzes the Global HIV Drugs market landscape and its growth prospects.

Key vendors dominating this market include Gliead Sciences Inc., Bristol-Myers Squibb Co., Abbott Laboratories, ViiV Healthcare.

Commenting on the report, an analyst from TechNavio's Healthcare team said, Major issues such as resistance to ART, patent expirations, and increasing HIV infections have created a need for novel drugs. The trend is moving towards development of new ART drugs that operate outside infected cells. This could include new class of drugs for entry inhibitors, coreceptor antagonists and fusion inhibitors.

According to the report, early initiation of Highly Active AntiRetroviral Therapy (HAART) is the most effective way to reduce the risk of blood-borne infections. New studies from British Columbia Centre for Excellence (BC-CfE) in HIV/AIDS, San Francisco, states that HAART was associated with a 50 percent decrease in new yearly HIV infections among injection drug users. This driver is expected to have a huge impact on the market.

Key findings from the report:

Increase in Prevalence of HIV Worldwide and Longer Life Expectancy of Patients
Lack of Complete Cure and Length of Therapy
Development of Immune-based therapies for HIV
The contents of this report are based on research conducted on an objective combination of primary and secondary scores, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a swot analysis of the key players.